A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of a Single Oral Dose of CDX-6114 in Patients With Phenylketonuria (PKU)
Latest Information Update: 27 Feb 2023
At a glance
- Drugs CDX-6114 (Primary)
- Indications Phenylketonuria
- Focus Pharmacodynamics
- Sponsors Nestle
Most Recent Events
- 11 Sep 2020 Status changed from recruiting to completed.
- 27 Jan 2020 Planned End Date changed from 31 Dec 2019 to 15 Aug 2020.
- 27 Jan 2020 Planned primary completion date changed from 31 Dec 2019 to 30 Jun 2020.